379 related articles for article (PubMed ID: 19322970)
1. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
Joshi SR; Sapatnekar SM
J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
[No Abstract] [Full Text] [Related]
2. A model for the future conduct of pharmacovigilance.
Waller PC; Evans SJ
Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844
[TBL] [Abstract][Full Text] [Related]
3. Reporting adverse effects: a practice to be encouraged.
Prescrire Int; 2013 Mar; 22(136):83. PubMed ID: 23593701
[No Abstract] [Full Text] [Related]
4. An underrecognized challenge in evaluating postmarketing drug safety.
Roden DM
Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
[No Abstract] [Full Text] [Related]
5. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
6. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
7. European commission consultation on pharmacovigilance.
Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
[No Abstract] [Full Text] [Related]
8. Advantages of adverse-effect reporting by patients.
Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
[No Abstract] [Full Text] [Related]
9. Adverse drug reaction monitoring in pediatric practice.
Kshirsagar NA; Karande S
Indian Pediatr; 1996 Dec; 33(12):993-8. PubMed ID: 9141798
[No Abstract] [Full Text] [Related]
10. Pharmacovigilance in clinical dentistry: overlooked or axiomatic?
Carnelio S; Khan SA; Rodrigues G
Gen Dent; 2011; 59(1):24-8; quiz 29-30, 80. PubMed ID: 21613036
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacovigilance: a case of phantom ships and Russian roulette].
Stricker BH
Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
[TBL] [Abstract][Full Text] [Related]
12. An adverse drug reaction reporting program.
Wasan SM; Marshall LB
Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
[No Abstract] [Full Text] [Related]
13. [Pharmacovigilance: theoretical and practical aspects].
Paoletti V; Galeotta G; Mammarella A
Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
[TBL] [Abstract][Full Text] [Related]
14. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
15. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
16. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing surveillance.
Vlahović-Palčevski V; Mentzer D
Handb Exp Pharmacol; 2011; 205():339-51. PubMed ID: 21882120
[TBL] [Abstract][Full Text] [Related]
18. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacovigilance update].
Livio F; Biollaz J; Buclin T
Rev Med Suisse; 2011 Jan; 7(277):71-4. PubMed ID: 21309181
[TBL] [Abstract][Full Text] [Related]
20. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
Mariani L; Minora T; Ventresca GP
Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
